Last reviewed · How we verify
VRS-317
At a glance
| Generic name | VRS-317 |
|---|---|
| Also known as | Growth Hormone Deficiency, rhGH, hGH, AGHD, IGF-I |
| Sponsor | Versartis Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD) (PHASE2)
- Long-Acting Growth Hormone in Children Compared to Daily rhGH (PHASE3)
- Versartis Trial in Children to Assess Long-Acting Growth Hormone (PHASE1, PHASE2)
- Versartis International Trial in Adults With Long-Acting Growth Hormone (PHASE2)
- Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317) (PHASE2, PHASE3)
- A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency (PHASE3)
- Versartis Long-Term Safety Study of Somavaratan (PHASE2, PHASE3)
- VRS-317 in Adult Subjects With Growth Hormone Deficiency (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VRS-317 CI brief — competitive landscape report
- VRS-317 updates RSS · CI watch RSS
- Versartis Inc. portfolio CI